ArticleJournal of experimental & clinical cancer research : CR2015

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.

Francesca Ferrari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.